Leukemia acute myeloblastic

TUMOR NECROSIS FACTOR ALPHA STIMULATES THE GROWTH OF THE CLONOGENIC CELLS OF ACUTE MYELOBLASTIC LEUKEMIA IN SYNERGY WITH GRANULOCYTE / MACROPHAGE COLONY -STIMULATING FACTOR... 

M1 Acute myeloblastic leukemia with minimal maturation 15 17 25... 

Matsuno, N., Osato, M., Yamashita, N., Yanagida, M., Nanri, T., Fukushima, T., Motoji, T., Kusumoto, S., Towatari, M., Suzuki, R., etal. (2003) Dual mutations in the AMLl and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the MO subtype. Leukemia 17, 2492-2499. 

Soon after the discovery of 1-ASP as an antineoplastic agent, its antitumor specificity was studied in patients with cancer. Unfortunately, only one tumor consistently responded to the drug childhood and adult ALL. Other tumors responded inconsistently, like acute myeloblastic leukemia (AML), non-Hodgkin s... 

Acute myeloblastic leukemia occurred in a 24-year-old man who had taken massive doses of amfetamine for more than 2 years (SED-8,13). 

Hess, C.E., Joyce, R.A. Acute myeloblastic leukemia presenting as progressive hepatic failure. South Med. J. 1981 74 1028-1029... 

In an open study in eight young healthy Japanese women, the pharmacokinetics of amikacin were affected by the phase of the menstrual cycle (12). In patients with hematological malignancies, bodyweight, renal function, acute myeloblastic leukemia, and hypoalbuminemia were the most important co-variates for the interindividual variability in amikacin pharmacokinetics (13). 

Katayama Y, Deguchi S, Shinagawa K, Teshima T, Notohara K, Taguchi K, Omoto E, Harada M. Bone marrow necrosis in a patient with acute myeloblastic leukemia during administration of G-CSF and rapid hematologic recovery after allotransplantation of peripheral blood stem cells. Am J Hematol 1998 57(3) 238 0. 

Soutar RL. Acute myeloblastic leukemia and recombinant granulocyte colony stimulating factor. BMJ 1991 ... 

A patient with acute myeloblastic leukemia, who took tioguanine for 2 months, developed severe peliosis hepatis associated with mild lesions of the centrilobular veins withdrawal was followed by progressive improvement of liver dysfunction (7). 

A syndrome similar to that of the retinoic acid syndrome occurred after 10 days of tretinoin therapy in a patient with a relapse of acute myeloblastic leukemia (31). 

A 75-year-old woman whose acute myeloblastic leukemia relapsed was treated with one dose of intravenous idarubicin (10 mg/m ), cytarabine 20 mg subcutaneously for 10 days, and oral tretinoin 45 mg/m /day. 

IL-9 can support cell proliferation in the absence of an antigen or APC, Overproduction of it may lead to T-cell tumors, particularly of Th2 lymphocytes. In certain lymphomas, such as Hodgkin s lymphoma, it may act as an autocrine signal for cellular proliferation. IL-9 may play a role in the development of acute myeloblastic leukemia by stimulating leukemic cells to enter the S-phase rather than preventing cell death. In addition, IL-9 acts synergisticaUy with stem cell factor for recruitmg quiescent leukemic cells in the cell cycle. ... 

Cheng GY, Minden MD, Toyonaga B, Mak TW, McCulloch EA. T cell receptor and immunoglobulin gene rearrangements in acute myeloblastic leukemia. 

As a medical application of poly(ADP-ribose) immunofluorescence, Ikai et al. reported that myeloblasts in peripheral blood as well as in bone marrow in patients with acute myeloblastic leukemia (AML) showed intense fluorescence of poly(ADP-ribose) in nuclei and that this was the case for blastic crisis of chronic myelocytic leukemia (CML)[13]. 

J. Mejer and P. Nygaard, Adenosine deaminase and purine nucleoside phosphorylase levels in acute myeloblastic leukemia cells. Relationship to diagnosis and clinical course Leukemia Res.. 3 211 (1979). 

Patients aged 60 years and older with acute myeloblastic leukemia in complete remission were randomly assigned to no further therapy or a 90-day regimen of 14-day cycles of low-dose rIL-2 ( = 66) of the latter, 24 stopped early because of adverse reactions or relapse [69 "]. Grade 4 reactions during rIL-2 therapy included thrombocytopenia (65%) and neutropenia (64%), and grade 3 reactions included anemia (33%), infections (24%), and malaise/ fatigue (14%). 

Kiss, Z., E. Deli, M. Shoji, H.P. Koeffler, G.R. Pettit, W.R. Vogler, and J.F. Kuo Differential Effects of Various Protein Kinase C Activators on Protein Phosphorylation in Human Acute Myeloblastic Leukemia Cell Line KG-1 and Its Phorbol Ester-resistant Subline KG-la. Cancer Res. 47, 1302 (1987). 

Cell-free extract of blast cells of a patient with acute myeloblastic leukemia... 

---